Literature DB >> 16142859

Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes.

John R Glossop1, Peter T Dawes, Andrew B Hassell, Derek L Mattey.   

Abstract

OBJECTIVE: To investigate whether polymorphisms in the tumor necrosis factor receptor I (TNFRSF1A) and receptor II (TNFRSF1B) genes are associated with the anemia observed in rheumatoid arthritis (RA).
METHODS: We studied a group of Caucasian patients (n = 160) with established RA on whom longitudinal data of hemoglobin (Hb) levels over 5 years were recorded. A second group of patients (n = 102) with early RA was used for a confirmation study. Polymerase chain reaction restriction fragment length polymorphism analysis was used to genotype patients for the A36G polymorphism in the TNFRSF1A gene, and the T676G polymorphism in TNFRSF1B. Serum levels of ferritin were determined by ELISA and used to differentiate between iron deficiency anemia (IDA) and anemia of chronic disease (ACD). Data were analyzed by Kruskal-Wallis analysis of variance and logistic regression analysis.
RESULTS: The TNFRSF1A GG genotype was associated with lower 5-year mean area under the curve Hb levels compared with other genotypes (p = 0.01). Analysis of anemic status showed an increased frequency of anemia in patients carrying a G allele, with the highest frequency in GG homozygotes. The TNFRSF1A GG genotype was significantly associated with IDA in established RA (OR 4.3, p = 0.01), and this was confirmed in a group of patients with early RA (OR 4.8, p = 0.04). Analysis of the combined groups also showed a weak association of the G allele with ACD (OR 2.2, p = 0.04). No association was found between TNFRSF1B variants and anemia when the cohorts were analyzed separately, but an association between carriage of the T allele and ACD was found when the 2 groups were combined (OR 11.5, p = 0.01).
CONCLUSION: Our data suggest that polymorphisms within the TNFRSF1A and TNFRSF1B genes are associated with IDA and/or ACD in patients with RA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16142859

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Anaemia in inflammatory rheumatic diseases.

Authors:  Günter Weiss; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

2.  Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Suleyman Serdar Koca; Ahmet Isik; Bilal Ustundag; Kerem Metin; Kader Aksoy
Journal:  Inflammation       Date:  2008-02-16       Impact factor: 4.092

3.  TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Authors:  Akiko Kuwahara; Motohiro Yamamori; Megumi Fujita; Tatsuya Okuno; Takao Tamura; Kaori Kadoyama; Noboru Okamura; Tsutomu Nakamura; Toshiyuki Sakaeda
Journal:  J Exp Clin Cancer Res       Date:  2010-07-20

4.  Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis.

Authors:  John R Glossop; Peter T Dawes; Nicola B Nixon; Derek L Mattey
Journal:  Arthritis Res Ther       Date:  2005-09-07       Impact factor: 5.156

5.  Hepatic Proteins and Inflammatory Markers in Rheumatoid Arthritis Patients.

Authors:  Manel Ben-Hadj-Mohamed; Souhir Khelil; Mokhles Ben Dbibis; Latifa Khlifi; Hend Chahed; Salima Ferchichi; Elyes Bouajina; Abdelhédi Miled
Journal:  Iran J Public Health       Date:  2017-08       Impact factor: 1.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.